ARID1A and gastric cancer: At the same time, there is another ongoing trial, which evaluates the single dose dual ICIs (tremelimumab and durvalumab), aiming at the increase of intra-tumoral T cells in ARID1A-mutant GC/EAC/GEJ adenocarcinomas, with the intra-tumoral effector T-cells (CD3/CD8) being evaluated after the single dose (2–6 weeks) versus baseline [148].